Meda Ab (MDABY) 19.2000 $MDABY MEDA: Notice to
Post# of 273254
Posted On: 09/24/2016 9:15:21 AM
Meda Ab (MDABY) 19.2000 $MDABY
MEDA: Notice to noteholders regarding change of control
BusinessWire - Fri Aug 05, 10:06AM CDT
Regulatory News:
Meda Aktiebolag (publ) applies for delisting and convenes an extraordinary general meeting
BusinessWire - Tue Aug 02, 10:23AM CDT
Regulatory News:
Extraordinary General Meeting of Meda Aktiebolag (publ)
BusinessWire - Tue Aug 02, 10:10AM CDT
Regulatory News:
Mylan Announces Pricing of Senior Notes
PR Newswire - Tue May 31, 4:24PM CDT
Mylan N.V. (NASDAQ, TASE: MYL) today announced the pricing of a private placement of $6.5 billion aggregate principal amount of senior notes, comprised of $1.0 billion aggregate principal amount of 2.50% senior notes due 2019 at an issue price of 99.888%, $2.25 billion aggregate principal amount of 3.15% senior notes due 2021 at an issue price of 99.884%, $2.25 billion aggregate principal amount of 3.95% senior notes due 2026 at an issue price of 99.231% and $1.0 billion aggregate principal amount of 5.25% senior notes due 2046 at an issue price of 99.984%. Mylan intends to use the net proceeds from the offering of notes to finance its previously announced public offer (the "Offer"
to acquire all of the outstanding shares of Meda AB (publ.) (the "Meda Acquisition" , to repay, prepay, redeem or otherwise refinance its or any of its subsidiaries' indebtedness (including that of Meda and its subsidiaries) (the "Refinancing" and to pay costs associated with the Meda Acquisition and the Refinancing, including non-periodic fees, costs and expenses, stamp registration and other taxes. Upon completion of the offering of the notes, Mylan intends to reduce the commitments under its Bridge Credit Agreement, dated as of Feb. 10, 2016, in an amount equal to the aggregate net proceeds from the offering of the notes. Subject to customary closing conditions, the sale of the notes is expected to close on or about June 9, 2016.
MYL: 42.06 (-0.53)
MEDA: Interim Report, January-March 2016
BusinessWire - Tue May 03, 1:18AM CDT
Regulatory News:
MEDA: Invitation to teleconference for analysts, investors and media
BusinessWire - Tue Apr 26, 6:12AM CDT
Regulatory News:
Meda AB (publ) AGM bulletin
BusinessWire - Thu Apr 14, 2:15PM CDT
Regulatory News:
Business Highlights
By The Associated Press - AP - Wed Feb 10, 5:45PM CST
___
WFM: 28.52 (-0.15), BUD: 130.16 (+0.10), TGT: 68.77 (+0.21), WMT: 72.35 (+0.08), ODP: 3.71 (+0.08)
Statement by the Board of Directors of Meda in relation to the public offer by Mylan
BusinessWire - Wed Feb 10, 5:29PM CST
Regulatory News:
Mylan to buy Sweden's Meda AB for $7.2 billion
AP - Wed Feb 10, 4:42PM CST
NEW YORK (AP) — Drugmaker Mylan says it will buy Meda AB of Sweden for $7.2 billion in cash and stock, and says the move will help it enter new markets.
ABT: 42.19 (-0.03), MYL: 42.06 (-0.53)
MEDA: Year-end Report, January-December 2015
BusinessWire - Wed Feb 10, 4:09PM CST
Regulatory News:
MEDA: Invitation to Teleconference for Analysts, Investors and Media
BusinessWire - Thu Feb 04, 4:47AM CST
Meda AB (STO:MEDAA) (Pink Sheets:MDABY)
MEDA completes divestment of Euromed manufacturing unit in Spain
M2 - Thu Dec 31, 5:21AM CST
Meda AB (STO:MEDAA) (Pink Sheets:MDABY) on Wednesday announced the completion of the divestment of its manufacturing unit Euromed in Spain.
MEDA: Divestment of Manufacturing Unit Euromed in Spain Completed
BusinessWire - Wed Dec 30, 1:09AM CST
Regulatory News:
Muscle Spasm Global Clinical Trials Review, H2, 2015 - Analysis & Technologies
M2 - Mon Dec 14, 5:59AM CST
Research and Markets (http://www.researchandmarkets.com/research/gsz2s9/muscle_spasm) has announced the addition of the "Muscle Spasm Global Clinical Trials Review, H2, 2015" report to their offering. This clinical trial report, Muscle Spasm Global Clinical Trials Review, H2, 2015" provides an overview of Muscle Spasm clinical trials scenario. This report provides top line data relating to the clinical trials on Muscle Spasm. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. The report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Clinical Trial Reports are generated using Our proprietary database - Pharma eTrack Clinical trials database. Key Topics Covered: - The report provides a snapshot of the global clinical trials landscape - Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status - The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company - The Report provides enrollment trends for the past five years - Report provides latest news for the past three months Benefits of this Report: - Assists in formulating key business strategies with regards to investment - Helps in identifying prominent locations for conducting clinical trials which saves time and cost - Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities - Supports understanding of trials count and enrollment trends by country in global therapeutics market - Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials - Facilitates clinical trial assessment of the indication on a global, regional and country level Companies Mentioned: - Themis Medicare Ltd. - Inventia Healthcare Private Limited - Allergan Plc - Flex Pharma, Inc. - Navipharm Co., Ltd - Meda AB - Ipsen S.A. - Eisai Co., Ltd. - Dr. Reddy's Laboratories Limited - Avigen, Inc. For more information visit http://www.researchandmarkets.com/research/gs...scle_spasm
AGN: 243.94 (+0.51), FLKS: 11.45 (-0.04)
Update on License Agreement between Meda and Valeant
BusinessWire - Mon Nov 16, 12:12AM CST
Regulatory News:
Meda reports profit after tax of SEK163m in Q3 2015
M2 - Fri Nov 06, 3:33AM CST
Meda AB (STO:MEDAA) (Pink Sheets:MDABY) on Thursday reported profit after tax of SEK163m, or EPS of SEK0.45, for the third quarter of 2015, from July 2015 to September 2015.
MEDA: Notice to noteholders regarding change of control
BusinessWire - Fri Aug 05, 10:06AM CDT
Regulatory News:
Meda Aktiebolag (publ) applies for delisting and convenes an extraordinary general meeting
BusinessWire - Tue Aug 02, 10:23AM CDT
Regulatory News:
Extraordinary General Meeting of Meda Aktiebolag (publ)
BusinessWire - Tue Aug 02, 10:10AM CDT
Regulatory News:
Mylan Announces Pricing of Senior Notes
PR Newswire - Tue May 31, 4:24PM CDT
Mylan N.V. (NASDAQ, TASE: MYL) today announced the pricing of a private placement of $6.5 billion aggregate principal amount of senior notes, comprised of $1.0 billion aggregate principal amount of 2.50% senior notes due 2019 at an issue price of 99.888%, $2.25 billion aggregate principal amount of 3.15% senior notes due 2021 at an issue price of 99.884%, $2.25 billion aggregate principal amount of 3.95% senior notes due 2026 at an issue price of 99.231% and $1.0 billion aggregate principal amount of 5.25% senior notes due 2046 at an issue price of 99.984%. Mylan intends to use the net proceeds from the offering of notes to finance its previously announced public offer (the "Offer"
to acquire all of the outstanding shares of Meda AB (publ.) (the "Meda Acquisition" , to repay, prepay, redeem or otherwise refinance its or any of its subsidiaries' indebtedness (including that of Meda and its subsidiaries) (the "Refinancing" and to pay costs associated with the Meda Acquisition and the Refinancing, including non-periodic fees, costs and expenses, stamp registration and other taxes. Upon completion of the offering of the notes, Mylan intends to reduce the commitments under its Bridge Credit Agreement, dated as of Feb. 10, 2016, in an amount equal to the aggregate net proceeds from the offering of the notes. Subject to customary closing conditions, the sale of the notes is expected to close on or about June 9, 2016. MYL: 42.06 (-0.53)
MEDA: Interim Report, January-March 2016
BusinessWire - Tue May 03, 1:18AM CDT
Regulatory News:
MEDA: Invitation to teleconference for analysts, investors and media
BusinessWire - Tue Apr 26, 6:12AM CDT
Regulatory News:
Meda AB (publ) AGM bulletin
BusinessWire - Thu Apr 14, 2:15PM CDT
Regulatory News:
Business Highlights
By The Associated Press - AP - Wed Feb 10, 5:45PM CST
___
WFM: 28.52 (-0.15), BUD: 130.16 (+0.10), TGT: 68.77 (+0.21), WMT: 72.35 (+0.08), ODP: 3.71 (+0.08)
Statement by the Board of Directors of Meda in relation to the public offer by Mylan
BusinessWire - Wed Feb 10, 5:29PM CST
Regulatory News:
Mylan to buy Sweden's Meda AB for $7.2 billion
AP - Wed Feb 10, 4:42PM CST
NEW YORK (AP) — Drugmaker Mylan says it will buy Meda AB of Sweden for $7.2 billion in cash and stock, and says the move will help it enter new markets.
ABT: 42.19 (-0.03), MYL: 42.06 (-0.53)
MEDA: Year-end Report, January-December 2015
BusinessWire - Wed Feb 10, 4:09PM CST
Regulatory News:
MEDA: Invitation to Teleconference for Analysts, Investors and Media
BusinessWire - Thu Feb 04, 4:47AM CST
Meda AB (STO:MEDAA) (Pink Sheets:MDABY)
MEDA completes divestment of Euromed manufacturing unit in Spain
M2 - Thu Dec 31, 5:21AM CST
Meda AB (STO:MEDAA) (Pink Sheets:MDABY) on Wednesday announced the completion of the divestment of its manufacturing unit Euromed in Spain.
MEDA: Divestment of Manufacturing Unit Euromed in Spain Completed
BusinessWire - Wed Dec 30, 1:09AM CST
Regulatory News:
Muscle Spasm Global Clinical Trials Review, H2, 2015 - Analysis & Technologies
M2 - Mon Dec 14, 5:59AM CST
Research and Markets (http://www.researchandmarkets.com/research/gsz2s9/muscle_spasm) has announced the addition of the "Muscle Spasm Global Clinical Trials Review, H2, 2015" report to their offering. This clinical trial report, Muscle Spasm Global Clinical Trials Review, H2, 2015" provides an overview of Muscle Spasm clinical trials scenario. This report provides top line data relating to the clinical trials on Muscle Spasm. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. The report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Clinical Trial Reports are generated using Our proprietary database - Pharma eTrack Clinical trials database. Key Topics Covered: - The report provides a snapshot of the global clinical trials landscape - Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status - The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company - The Report provides enrollment trends for the past five years - Report provides latest news for the past three months Benefits of this Report: - Assists in formulating key business strategies with regards to investment - Helps in identifying prominent locations for conducting clinical trials which saves time and cost - Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities - Supports understanding of trials count and enrollment trends by country in global therapeutics market - Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials - Facilitates clinical trial assessment of the indication on a global, regional and country level Companies Mentioned: - Themis Medicare Ltd. - Inventia Healthcare Private Limited - Allergan Plc - Flex Pharma, Inc. - Navipharm Co., Ltd - Meda AB - Ipsen S.A. - Eisai Co., Ltd. - Dr. Reddy's Laboratories Limited - Avigen, Inc. For more information visit http://www.researchandmarkets.com/research/gs...scle_spasm
AGN: 243.94 (+0.51), FLKS: 11.45 (-0.04)
Update on License Agreement between Meda and Valeant
BusinessWire - Mon Nov 16, 12:12AM CST
Regulatory News:
Meda reports profit after tax of SEK163m in Q3 2015
M2 - Fri Nov 06, 3:33AM CST
Meda AB (STO:MEDAA) (Pink Sheets:MDABY) on Thursday reported profit after tax of SEK163m, or EPS of SEK0.45, for the third quarter of 2015, from July 2015 to September 2015.
(0)
(0)Scroll down for more posts ▼